HA280 immunoadsorption, an alternative treatment for neuromyelitis optica spectrum disorders?

Abstract

We report a case of neuromyelitis optica spectrum disorders (NMOSD) with complete loss of vision in the left eye in a patient who was not satisfied with the effect of methylprednisolone therapy, which was improved by HA280 immunoadsorption (IA) therapy. HA280 is a relatively cheaper IA column (made in China) often used in the treatment of rheumatoid immune-related diseases. HA280 can effectively remove inflammatory markers in serum. However, whether the HA280 IA column is suitable for NMOSD is unknown. This case suggests that the HA280 IA column has a potential therapeutic effect on NMOSD and may be an alternative treatment for steroid-resistant NMOSD. There may be therapeutic targets other than anti-AQP4 antibody. Identifying the inflammatory substances that could be removed to contribute to NMOSD recovery is worthy of further study, and the results could provide new ideas for acute NMOSD treatment. Moreover, the HA280 IA column is relatively cheap and allows lower-income families to use it.

• Authors: Shuangxi Liu, Jun Zhou, Qin Liu, Yao Yang, Mingxia Li, Rongyong Man, Junjie Yin
• Journal: Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 37 Pg. 101480 (Jan 2020) ISSN: 2211-0356 [Electronic] Netherlands
• PMID: 31706165 (Publication Type: Case Reports)
• Copyright: Copyright © 2019 Elsevier B.V. All rights reserved.

Topics

• Adult
• Blindness (etiology)
• Female
• Humans
• Neuromyelitis Optica (complications, therapy)
• Plasmapheresis (instrumentation)